A systematic review of adverse events in the placebo arm of donepezil trials: The role of cognitive impairment

International Psychogeriatrics

Volumn 24, Issue 5, 2012, Pages 698-707

  Amanzio, Martina ^a,b   Benedetti, Fabrizio ^c,d   Vase, Lene ^e,f  

^a UNIVERSITY OF TURIN   (Italy)

^b Neuroscience Institute of Turin NIT   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d National Institute of Neuroscience INN   (Italy)

^e AARHUS UNIVERSITY   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alzheimer's disease; mild cognitive impairment; nocebo; randomized controlled trials

Indexed keywords

DONEPEZIL; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABRASION; ACCIDENTAL INJURY; ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; APPLICATION SITE EXCORIATION; ARTHRALGIA; ARTHRITIS; ASTHENIA; BACKACHE; BODY WEIGHT; BRADYCARDIA; BRONCHITIS; CARDIOVASCULAR DISEASE; CHEST INFECTION; COMMON COLD; COMPARATIVE STUDY; CONFUSION; CONJUNCTIVITIS; CONSTIPATION; CONTUSION; CORONARY ARTERY DISEASE; COUGHING; CREATINE KINASE BLOOD LEVEL; CYSTITIS; DEPRESSION; DIARRHEA; DISEASE PREDISPOSITION; DIZZINESS; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPEPSIA; ECCHYMOSIS; ECZEMA; EDEMA; FATIGUE; FEMUR FRACTURE; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; LEG CRAMP; MEDLINE; MILD COGNITIVE IMPAIRMENT; MUSCLE CRAMP; MYASTHENIA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECORDING; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SINUS BRADYCARDIA; SKIN ULCER; STROKE; STUPOR; SYNCOPE; SYSTEMATIC REVIEW; TREMOR; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE; VALIDITY; VERTIGO;

AGED; ALZHEIMER DISEASE; HUMANS; INDANS; MILD COGNITIVE IMPAIRMENT; NOOTROPIC AGENTS; PIPERIDINES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859116638     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610211002420     Document Type: Review

References (43)

1. Amanzio, M. (2011). Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials? Recent Patents on CNS Drug Discovery, 6, 41-47.
2. Amanzio, M., Latini Corazzini, L., Vase, L. and Benedetti, F. (2009). A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain, 146, 261-269.
3. Amanzio, M. et al. (2011). Unawareness of deficits in Alzheimer's disease: role of the cingulate cortex. Brain, 134, 1061-1076.
4. Andrykowski, M. and Redd, W. (1987). Longitudinal analysis of the development of anticipatory nausea. Journal of Consulting & Clinical Psychology, 55, 36-41.
5. Benedetti, F. and Amanzio, M. (1997). The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Progress in Neurobiology, 52, 109-125. (Pubitemid 27242702)
6. Benedetti, F., Lanotte, M., Lopiano, L. and Colloca, L. (2007). When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience, 147, 260-271. (Pubitemid 46907442)
7. Black, S. E. et al. (2007). Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology, 69, 459-469. (Pubitemid 47450281)
8. Burns, A. et al. (1999). The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dementia & Geriatric Cognitive Disorders, 10, 237-244. (Pubitemid 29224502)
9. Cepeda, M. S., Farrar, J. T., Baumgarten, M., Boston, R., Carr, D. B. and Strom, B. L. (2003). Side effects of opioids during short-term administration: effect of age, gender and race. Clinical Pharmacology & Therapeutics, 74, 102-112.
10. Davis, C., Ralevski, E., Kennedy, S. H. and Neitzert, C. S. (1995). The role of personality factors in the reporting of side effect complaints to moclobemide and placebo. Journal of Clinical Psychopharmacology, 15, 347-352.
11. de la Cruz, M., Hui, D., Parsons, H. A. and Bruera, E. (2010). Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer, 116, 766-774.
12. Doody, R. S. et al. (2009). Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology, 72, 1555-1561.
13. Doody, R. S. et al. (2010). Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. American Journal of Alzheimers Disease & Other Dementias, 25, 155-159.
14. Doraiswamy, M., Leon, J., Cummings, J. L., Martin, D. and Neumann, PJ. (2002). Prevalence and impact of medical comorbidity in Alzheimer's disease. The Journals of Gerontology Series A, Biological Sciences and Medical Sciences, 57, 73-77.
15. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P. and Whalen, E. (2001). Donepezil MSAD study investigators group: a 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57, 613-620. (Pubitemid 32782987)
16. Ferguson, J.M. (1993). Alprazolam XR: patient acceptability, safety, and tolerability. Psychiatric Annals, 23, 20-26.
17. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
18. Fried, L. P. et al. (2001). Cardiovascular health study collaborative research group. Frailty in older adults: evidence for a phenotype. Journals of Gerontology Series A, Biological Sciences and Medical Sciences, 56, M146-M156.
19. Harrington, A. (ed.) (1997) The Placebo Effect: An Interdisciplinary Exploration. Cambridge, MA: Harvard University Press.
20. Hilmer, S. N., McLachlan, A. J. and Le Couteur, D. G. (2007). Clinical pharmacology in the geriatric patient. Fundamental Clinical Neuropharmacology, 21, 217-230.
21. Homma, A. et al. (2000). Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 study group. Dementia and Geriatric Cognitive Disorders, 11, 299-313.
22. Homma, A. et al. (2008). Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dementia and Geriatric Cognitive Disorders, 25, 399-407. (Pubitemid 351630073)
23. Howard, R. J. et al. (2007). CALM-AD trial group. Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357, 1382-1392. (Pubitemid 47535593)
24. Jadad, A. R. et al. (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials, 17, 1-12. (Pubitemid 26120810)
25. Johannsen, P. et al. (2006). Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs, 20, 311-325.
26. Mazza, M., Capuano, A., Bria, P. and Mazza, S. (2006). Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. European Journal of Neurology, 13, 981-985. (Pubitemid 44284905)
27. McLean, A. J. and Le Couteur, D. G. (2004). Ageing biology and geriatric clinical pharmacology. Pharmacological Reviews, 56, 163-184.
28. Mohs, R. C. et al. (2001). "312" study group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481-488. (Pubitemid 32757597)
29. Petersen, R. C. et al. (2005). Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine, 352, 2379-2388. (Pubitemid 40958434)
30. Raschetti, R., Albanese, E., Vanacore, N. and Maggini, M. (2007). Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomized trials. PLoS Medicine, 4, 1818-1828. (Pubitemid 350220534)
31. Rief, W. et al. (2009). Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Safety, 32, 1041-1056.
32. Rogers, S. L. and Friedhoff, L.T. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia, 7, 293-303. (Pubitemid 26341258)
33. Rogers, S. L., Doody, R. S., Mohs, R. C. and Friedhoff, L. T. (1998a). Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Archives of Internal Medicine, 158, 1021-1031.
34. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. and Friedhoff, LT. (1998b). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology, 50, 136-45.
35. Salloway, S. et al. (2004). Donepezil 401 study group. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology, 63, 651-657. (Pubitemid 39100820)
36. Seltzer, B. et al. (2004). Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Archives of Neurology, 61, 1852-1856. (Pubitemid 39612945)
37. Standaert, D. G. and Young, A. B. (1996). Treatment of central nervous system degenerative disorders. In J. G. Hardman and L. E. Limbird (eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics (pp. 503-519). New York: Mc Graw-Hill.
38. Tariot, P. N. et al. (2001). A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society, 49, 1590-1599. (Pubitemid 34007984)
39. Waldemar, G. et al. (2007). Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guidelines. European Journal of Neurology, 14, e1-e26. (Pubitemid 46088015)
40. Walston, J. et al. (2006). Research agenda for frailty in older adults: toward a better understanding of physiology and etiology. Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. Journal of the American Geriatrics Society, 54, 991-1001. (Pubitemid 43847040)
41. Winblad, B. et al. (2001). Donepezil Nordic study group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57, 489-495. (Pubitemid 32757598)
42. Winblad, B. et al. (2006). Severe Alzheimer's disease study group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet, 367, 1057-1065.
43. Wolf, S. and Pinsky, R. M. (1954). Effects of placebo administration and occurrence of toxic reactions. JAMA, 155, 339-341.